Untitled
esquerda


Leia a Última Edição!

II Serie Volume 34 Number 4
April 2021

E-ALERT:

menu esquerda
 
   
 
 
 
 


  1- Factors of recurrence of intraepithelial lesions of the uterine cervix.

2- Duodenoscopy and endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of biliary and pancreatic pathology.

3- Mephedrone (?Meow Meow?), The New Designer Drug of Abuse: Pharmacokinetics, Pharmacodynimics and Clinical and Forensic Issues

4- Natural history of fetal pyelocaliectasia.

5- Antidepressant drugs.

6- Erysipelas.

7- Pressure ulcer management--Evidence-based interventions.

8- Traumatic Brain Injury: Integrated Approach

9- Genital ulcers caused by sexually transmitted diseases: current therapies, diagnosis and their relevance in HIV pandemy.

10- Current management of gout.

11- Livedo vasculitis.

12- Tarlov's cyst: definition, etiopathogenesis, propaedeutic and treatment.

13- Antibiotic treatment of uncomplicated cystitis in non-pregnant women up to menopause.

14- Urolithiasis and renal colic. Therapeutic approach in urology.

15- Uterine inversion.

16- Surgical basic skills: surgical sutures.

17- Intrahepatic cholestasis in pregnancy. Its etiopathogenesis, prognosis and therapy.

18- Necrotizing Pneumonia ? A Rare Complication

19- Shoulder dystocia: an obstetrical emergency.

20- Antihypertensive treatment in pregnancy.

 
   

Prevalence of Fear of Death among Young Breast Cancer Patients during Adjuvant Endocrine Therapy: Results from a Portuguese Cohort



A breast cancer diagnosis can greatly impact many young women and trigger a series of psychological and social challenges, particularly a fear of death or recurrence. This type of fear can cause physical and mental disorders affecting quality of life (QOL) in those with breast cancer. Endocrine therapy (ET) has also been associated with the worsening of anxiety symptoms. The precipitating factors must be recognized and identified in order to develop appropriate strategies for these patients. Both QOL and the impact of ET can be measured through questionnaires. The Functional Assessment of Cancer Treatment (FACT) and its endocrine subscale, FACT-ES v4, are validated QOL questionnaires specific to women with both breast cancer and endocrine symptoms.

Click here for the full Letter to the Editor.